Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jun 25, 2022
Discovery & Translation

Expanding the CAR T cell toolbox

Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies 
BioCentury | May 20, 2022
Discovery & Translation

Precision’s chronic HBV gene therapy; plus Blaze and ASGCT highlights

BioCentury’s roundup of translational news
BioCentury | Apr 29, 2022
Discovery & Translation

Cleavage resistant, regulatable CARs; plus Repertoire, Merus and more

BioCentury’s roundup of translational news
BioCentury | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

BioCentury | Aug 24, 2018
Politics, Policy & Law

The Louisiana purchase

How Louisiana is leading the way in innovative drug payment models
Items per page:
1 - 10 of 71